MINI-FUTURE LONG - ELI LILLY & CO | Market Closed - Swiss Exchange 11:20:00 2024-06-14 EDT | ||
| 3.56 CHF | +1.14% |
|
| Current month | +16.72% | ||
| 1 month | +42.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 3.56 | +1.14% |
| 24-06-13 | 3.52 | +3.23% |
| 24-06-11 | 3.41 | +1.19% |
| 24-06-10 | 3.37 | +2.43% |
| 24-06-07 | 3.29 | +2.81% |
Delayed Quote Swiss Exchange
Last update June 14, 2024 at 11:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYCNU | |
| ISIN | CH1292908659 |
| Date issued | 2023-09-01 |
| Strike | 483.6 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.89 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 3.56 CHF |
|---|---|
| Lowest since issue | 0.64 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.28% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Certificates
- LLYCNU Certificat
